ClinicalTrials.gg
CompletedNCT01794520Updated Apr 10, 2023Results posted

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1/2 interventional study of Venetoclax and Dexamethasone in Relapsed/Refractory Multiple Myeloma, sponsored by AbbVie. Completed at 29 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-10.

Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
117
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing venetoclax in Multiple Myeloma — 4 open to participants now, 9 under way, 2 of them phase 3. venetoclax · Multiple Myeloma.

Enrollment
6th of 20
117 · median 42
Started
2012
with 1 other
Phase 1/2
7 of 20
1 open now
Registered
1st of 20
by date
Lead sponsor
10 of 20
AbbVie

Among the 20 studies testing venetoclax in Multiple Myeloma, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 1/2, and was the 1st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

4 of the 20 studies testing venetoclax in Multiple Myeloma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing venetoclax in Multiple Myeloma, or all of them as a file.
02

Study summary

The Phase 1 primary objectives of this study were to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study also assessed the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma.

The Phase 2 primary objective was to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in participants with t(11;14)-positive multiple myeloma.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

Keywords

  • Relapsed multiple myeloma
  • Refractory multiple myeloma
  • Multiple myeloma
  • Relapsed/refractory multiple myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (Eastern Cooperative Oncology Group) performance score of 1 or 0. Participants in the Phase 2 portion: ECOG performance score of 2, 1, or 0.
  • Diagnosis of multiple myeloma (MM) previously treated with at least one .

    • Induction therapy followed by stem cell transplant and maintenance therapy will be considered a single line of therapy.
    • For Safety Expansion, participants must have been previously treated with a proteasome inhibitor (e.g., bortezomib) and an immunomodulatory agent (e.g., thalidomide, lenalidomide).
    • For Venetoclax-Dexamethasone Combination, participants must have been previously treated with a proteasome inhibitor (e.g., bortezomib) and an immunomodulatory agent (e.g., thalidomide, lenalidomide) AND have t(11;14)-positive multiple myeloma per the central lab testing.
    • For Phase 2, participants must have MM positive for the t(11;14) translocation, as determined by an analytically validated fluorescence in situ hybridization (FISH) assay per the central laboratory testing (enrollment with local t(11;14)-positive FISH results only will be considered at the discretion of the Therapeutic Area MD). Participants must have evidence of disease progression on or within 60 days of last dose of most recent previous treatment based on International Myeloma Working Group (IMWG) criteria AND must have previously received at least 2 lines of therapy, including an immunomodulatory drug (lenalidomide or pomalidomide), a proteasome inhibitor (bortezomib, carfilzomib or ixazomib), daratumumab, and .

      • For US participants: Daratumumab combination regimen must be one of the prior lines of therapy (for this study, daratumumab plus corticosteroids will not be considered a combination regimen).
      • For Non-US participants: Either daratumumab monotherapy or combination therapy is acceptable. Daratumumab monotherapy will be limited to approximately 20 percent of the total number of Phase 2 participants.
  • at Screening:

    • Serum monoclonal protein of at least 1.0 g/dL (10g/L) by protein electrophoresis.
    • At least 200 mg of monoclonal protein in the urine on 24-hr electrophoresis.
    • Serum immunoglobulin free light chain of at least 10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio.
  • Participants with a history of autologous or allogenic stem cell transplantation must have adequate peripheral blood counts independent of any growth factor support, and have recovered from any transplant related toxicity(s) and be:

    • At least 100 days post- transplant prior to first dose of study drug or
    • At least 6 months post-allogenic transplant prior to first dose of study drug and not have active (GVHD), i.e., requiring treatment.
  • Meet the following laboratory parameters, per the reference range, at least once during the screening period:

    • (ANC) of at least 1000/μL (Participants may use growth factor support to achieve ANC eligibility criteria).
    • (AST) and Alanine aminotransferase (ALT) not higher than 3 x (ULN).
    • Calculated of at least 30 mL/min using a modified Cockcroft-Gault calculation.
    • count of at least 30,000 mm³ (independent of transfusion for 2 weeks).
    • of at least 8.0 g/dL (participants may receive blood transfusion to achieve hemoglobin eligibility criteria).
    • Total not higher than 1.5 x ULN (Participants with Gilbert's Syndrome may have bilirubin higher than 1.5 x ULN).

Exclusion criteria

Exclusion Criteria:

  • Exhibits evidence of other uncontrolled condition(s), including, but not limited to:

    • Acute infection within 14 days prior to first dose of study drug requiring antibiotic, antifungal, or antiviral therapy.
    • Diagnosis of fever and neutropenia within 1 week prior to first dose of study drug.
  • Cardiovascular disability status of Class ≥ 3.
  • Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular or hepatic disease, within the last 6 months that, in the opinion of the investigator, would adversely affect his/her participation in the study.
  • History of other active other than multiple myeloma within the past 3 years prior to study entry, with the following exceptions:

    • Adequately treated in situ carcinoma of the cervix uteri;
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Localized prostate cancer Gleason grade 6 or lower AND with stable prostate specific antigen (PSA) levels off treatment
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  • Known Human Immunodeficiency Viral () infection.
  • Active or C infection.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Phase 1: Venetoclax 300 mg

    Participants in the dose-escalation cohort received 300 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.

    Drug: Venetoclax

  • Experimental
    Phase 1: Venetoclax 600 mg

    Participants in the dose-escalation cohort received 600 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.

    Drug: Venetoclax

  • Experimental
    Phase 1: Venetoclax 900 mg

    Participants in the dose-escalation cohort received 900 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.

    Drug: Venetoclax

  • Experimental
    Phase 1: Venetoclax 1200 mg

    Participants in the dose-escalation cohort received 1200 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.

    Drug: Venetoclax

  • Experimental
    Phase 1 Safety Expansion: Venetoclax 1200 mg

    Participants in the safety expansion cohort received 1200 mg of venetoclax daily on Days 1 - 21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.

    Drug: Venetoclax

  • Experimental
    Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg

    Participants with t(11;14) translocation multiple myeloma received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).

    Drug: Venetoclax · Drug: Dexamethasone

  • Experimental
    Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg

    The Phase 2 cohort further explored the efficacy of venetoclax in combination with dexamethasone in relapsed or refractory participants with t(11;14) translocation multiple myeloma. Participants received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).

    Drug: Venetoclax · Drug: Dexamethasone

Interventions

  • Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.

    Also known as: ABT-199, VENCLEXTA®

  • Tablets were administered by mouth per the dexamethasone prescribing information.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

    Time frame: From first dose of study drug until 30 days following last dose of study drug (up to 2482 days)

  2. Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax

    Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.

    Time frame: Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose

  3. Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax

    Tmax is the the time at which the maximum plasma concentration (Cmax) is observed.

    Time frame: Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose

  4. Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax

    AUC is a measure of how long and how much drug is present in the body after dosing.

    Time frame: Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose (dose escalation cohort); (1200 mg dose): Cycle 2, Day 1 at predose (safety expansion cohort, 1200 mg dose)

  5. Phase 2: Overall Response Rate

    Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria.

    Time frame: Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 31.7 months

  6. Phase 2: Very Good Partial Response Rate or Better

    The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria was computed.

    Time frame: Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 31.7 months

Secondary outcomes

  1. Phase 1: Overall Response Rate

    Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2011 International Myeloma Working Group (IMWG) criteria.

    Time frame: Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 8.1 months

  2. Time to Response (TTR)

    TTR is defined as the number of days from the date of first dose of study drug until the date of their first favorable response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2011 International Myeloma Working Group (IMWG) criteria (Phase 1) or 2016 IMWG criteria (Phase 2). If a participant did not experience a favorable response, they were to be censored at the date of last adequate assessment. TTR was analyzed by Kaplan- Meier (K-M)\\ methodology.

    Time frame: Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; Estimated median time on follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2

  3. Time to Progression (TTP)

    TTP is defined as the number of days from the date of first dose of study drug to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. TTP was analyzed by Kaplan- Meier (K-M) methodology.

    Time frame: Estimated median duration of follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2

  4. Duration of Response

    DOR is defined as the number of days from the date of first response of Partial Response (PR) or better to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan- Meier (K-M) methodology.

    Time frame: Assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median duration of follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2

  5. Phase 2: Progression-Free Survival (PFS)

    PFS is defined as the number of days from the date of the first dose of study treatment to the date of first documented disease progression or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.

    Time frame: Estimated median duration of follow-up was 31.7 months

  6. Phase 2: Overall Survival (OS)

    OS is defined as the number of days from the date of the first dose of study drug to the date of death due to any cause. If a participant was not known to have died, OS was censored at the last known alive date. The distribution of OS was estimated using Kaplan-Meier methodology.

    Time frame: Estimated median duration of follow-up was 31.7 months

  7. Phase 2: Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain

    The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its "worst in last 24 hours," "least in last 24 hours," "average," and "now" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.

    Time frame: Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit

  8. Phase 2: Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as "not at all" and 4 as "very much." The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.

    Time frame: Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit

  9. Phase 2: Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

    The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as "very poor" and 7 as "excellent." The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.

    Time frame: Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit

  10. Phase 2: Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score

    PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \[PROMIS\] Cancer Fatigue Short Form \[SF\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.

    Time frame: Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit

07

Results

Posted Apr 10, 2023

Participant flow

Participant flow — Overall Study
MilestonePhase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Started6969362031
Completed0000000
Not completed6969362031
Withdrew: Adverse events- related to progression0012010
Withdrew: Adverse event- not related to progression1100200
Withdrew: Progressive disease562527180
Withdrew: Withdrew consent0011000
Withdrew: Lost to follow-up0000100
Withdrew: Toxicity0200000
Withdrew: Study terminated by sponsor0010107
Withdrew: Death00001022
Withdrew: Other, not specified0011412

Outcome measures

PrimaryNumber of Participants With Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.

Time frame:
From first dose of study drug until 30 days following last dose of study drug (up to 2482 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsPhase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Any TEAE6969361930
TESAE143315616
PrimaryPhase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax

Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.

Time frame:
Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose
Reported as:
Mean · µg/mL
Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax
µg/mL300 mg Venetoclax600 mg Venetoclax900 mg Venetoclax1200 mg Venetoclax
Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax0.897 ± 0.5932.56 ± 1.771.85 ± 1.304.16 ± 1.52
PrimaryPhase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax

Tmax is the the time at which the maximum plasma concentration (Cmax) is observed.

Time frame:
Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose
Reported as:
Median · hours
Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax
hours300 mg Venetoclax600 mg Venetoclax900 mg Venetoclax1200 mg Venetoclax
Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax5.0 (2.0 to 8.0)8.0 (2.7 to 8.0)6.0 (4.0 to 8.0)6.1 (4.0 to 8.0)
PrimaryPhase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax

AUC is a measure of how long and how much drug is present in the body after dosing.

Time frame:
Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose (dose escalation cohort); (1200 mg dose): Cycle 2, Day 1 at predose (safety expansion cohort, 1200 mg dose)
Reported as:
Mean · µg•h/mL
Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax
µg•h/mL300 mg Venetoclax600 mg Venetoclax900 mg Venetoclax1200 mg Venetoclax
Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax13.0 ± 8.3138.2 ± 25.126.3 ± 20.171.5 ± 35.8
PrimaryPhase 2: Overall Response Rate

Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria.

Time frame:
Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 31.7 months
Reported as:
Number · percentage of participants
Phase 2: Overall Response Rate
percentage of participantsPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Phase 2: Overall Response Rate48.4 (30.2 to 66.9)
PrimaryPhase 2: Very Good Partial Response Rate or Better

The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria was computed.

Time frame:
Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 31.7 months
Reported as:
Number · percentage of participants
Phase 2: Very Good Partial Response Rate or Better
percentage of participantsPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Phase 2: Very Good Partial Response Rate or Better35.5 (19.2 to 54.6)
SecondaryPhase 1: Overall Response Rate

Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2011 International Myeloma Working Group (IMWG) criteria.

Time frame:
Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 8.1 months
Reported as:
Number · percentage of participants
Phase 1: Overall Response Rate
percentage of participantsPhase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Phase 1: Overall Response Rate0 (0.0 to 45.9)11.1 (0.3 to 48.2)16.7 (0.4 to 64.1)0 (0.0 to 33.6)36.1 (20.8 to 53.8)65.0 (40.8 to 84.6)
SecondaryTime to Response (TTR)

TTR is defined as the number of days from the date of first dose of study drug until the date of their first favorable response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2011 International Myeloma Working Group (IMWG) criteria (Phase 1) or 2016 IMWG criteria (Phase 2). If a participant did not experience a favorable response, they were to be censored at the date of last adequate assessment. TTR was analyzed by Kaplan- Meier (K-M)\\ methodology.

Time frame:
Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; Estimated median time on follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2
Reported as:
Median · months
Time to Response (TTR)
monthsPhase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Time to Response (TTR)—NA (1.9 to NA)NA (1.2 to NA)—9.0 (1.9 to NA)2.6 (1.4 to NA)0.8 (0.7 to NA)
SecondaryTime to Progression (TTP)

TTP is defined as the number of days from the date of first dose of study drug to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. TTP was analyzed by Kaplan- Meier (K-M) methodology.

Time frame:
Estimated median duration of follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2
Reported as:
Median · months
Time to Progression (TTP)
monthsPhase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Time to Progression (TTP)5.0 (3.9 to NA)2.0 (0.5 to NA)1.2 (0.4 to NA)1.9 (0.5 to NA)4.2 (1.9 to 10.2)12.2 (4.2 to 20.9)11.2 (5.2 to 18.4)
SecondaryDuration of Response

DOR is defined as the number of days from the date of first response of Partial Response (PR) or better to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan- Meier (K-M) methodology.

Time frame:
Assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median duration of follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2
Reported as:
Median · months
Duration of Response
monthsPhase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Duration of Response—9.7 (NA to NA)NA (NA to NA)—17.3 (7.8 to 27.0)13.1 (5.7 to 21.9)17.5 (7.6 to 28.8)
SecondaryPhase 2: Progression-Free Survival (PFS)

PFS is defined as the number of days from the date of the first dose of study treatment to the date of first documented disease progression or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.

Time frame:
Estimated median duration of follow-up was 31.7 months
Reported as:
Median · months
Phase 2: Progression-Free Survival (PFS)
monthsPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Phase 2: Progression-Free Survival (PFS)11.2 (5.2 to 18.4)
SecondaryPhase 2: Overall Survival (OS)

OS is defined as the number of days from the date of the first dose of study drug to the date of death due to any cause. If a participant was not known to have died, OS was censored at the last known alive date. The distribution of OS was estimated using Kaplan-Meier methodology.

Time frame:
Estimated median duration of follow-up was 31.7 months
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Phase 2: Overall Survival (OS)18.4 (8.2 to 24.3)
SecondaryPhase 2: Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain

The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its "worst in last 24 hours," "least in last 24 hours," "average," and "now" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.

Time frame:
Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit
Reported as:
Mean · units on a scale
Phase 2: Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain
units on a scalePhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Cycle 3, Day 10.2 ± 2.47
Cycle 5, Day 1-0.9 ± 1.43
Cycle 7, Day 1-0.9 ± 1.20
Cycle 9, Day 1-0.9 ± 1.46
Cycle 11, Day 1-1.1 ± 1.62
Cycle 13, Day 10.5 ± 3.84
Cycle 15, Day 1-0.6 ± 1.27
Cycle 17, Day 1-1.6 ± 1.29
Cycle 19, Day 1-1.8 ± 2.00
Cycle 21, Day 1-1.6 ± 2.30
Cycle 23, Day 1-1.6 ± 2.30
Cycle 25, Day 1-3.8
Final visit-0.3 ± 1.86
SecondaryPhase 2: Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as "not at all" and 4 as "very much." The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.

Time frame:
Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit
Reported as:
Mean · units on a scale
Phase 2: Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
units on a scalePhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Cycle 3, Day 1-3.7 ± 21.90
Cycle 5, Day 14.0 ± 15.78
Cycle 7, Day 18.3 ± 11.13
Cycle 9, Day 18.3 ± 11.13
Cycle 11, Day 115.2 ± 9.97
Cycle 13, Day 111.4 ± 14.76
Cycle 15, Day 114.3 ± 11.17
Cycle 17, Day 18.9 ± 13.11
Cycle 19, Day 1-0.0 ± 11.55
Cycle 21, Day 1-13.3 ± 28.28
Cycle 23, Day 1-3.3 ± 14.14
Cycle 25, Day 16.7
Final visit-5.0 ± 19.40
SecondaryPhase 2: Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)

The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as "very poor" and 7 as "excellent." The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.

Time frame:
Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit
Reported as:
Mean · units on a scale
Phase 2: Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
units on a scalePhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Cycle 3, Day 1-5.2 ± 25.44
Cycle 5, Day 16.7 ± 5.27
Cycle 7, Day 13.1 ± 7.63
Cycle 9, Day 18.3 ± 11.79
Cycle 11, Day 10.0 ± 11.79
Cycle 13, Day 1-6.0 ± 6.30
Cycle 15, Day 14.8 ± 8.13
Cycle 17, Day 1-1.4 ± 12.27
Cycle 19, Day 1-19.4 ± 4.81
Cycle 21, Day 1-33.3 ± 23.57
Cycle 23, Day 1-8.3 ± 0.00
Cycle 25, Day 1-8.3
Final visit-11.5 ± 23.55
SecondaryPhase 2: Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score

PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \[PROMIS\] Cancer Fatigue Short Form \[SF\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.

Time frame:
Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit
Reported as:
Mean · T-score
Phase 2: Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score
T-scorePhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
Cycle 3, Day 10.6 ± 5.88
Cycle 5, Day 1-2.9 ± 5.30
Cycle 7, Day 1-1.8 ± 4.21
Cycle 9, Day 1-1.6 ± 4.85
Cycle 11, Day 10.1 ± 7.24
Cycle 13, Day 11.0 ± 4.54
Cycle 15, Day 1-3.4 ± 5.69
Cycle 17, Day 10.6 ± 7.36
Cycle 19, Day 16.6 ± 2.25
Cycle 21, Day 111.6 ± 6.51
Cycle 23, Day 16.0 ± 0.57
Cycle 25, Day 15.6
Final visit1.4 ± 6.51

Adverse events

Collected over All-cause mortality is reported from enrollment to end of study; median time on follow up was 6.6, 3.4, 3.8, 3.0, 11.0, 13.2, and 31.7 months for Phase 1 300 mg Ven, Phase 1 600 mg Ven, Phase 1 900 mg Ven, Phase 1 1200 mg Ven, Phase 1 Safety Expansion Ven 1200 mg, Phase 1 Combination Ven 800 mg/Dex, and Phase 2 Expansion Ven 800 mg/Dex, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Venetoclax 300 mg1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Phase 1: Venetoclax 600 mg1/9 (11.1%)4/9 (44.4%)9/9 (100%)
Phase 1: Venetoclax 900 mg1/6 (16.7%)3/6 (50%)6/6 (100%)
Phase 1: Venetoclax 1200 mg0/9 (0%)3/9 (33.3%)9/9 (100%)
Phase 1 Safety Expansion: Venetoclax 1200 mg6/36 (16.7%)15/36 (41.7%)35/36 (97.2%)
Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg1/20 (5%)6/20 (30%)19/20 (95%)
Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg22/31 (71%)16/31 (51.6%)27/31 (87.1%)
Most frequent serious events
Showing 10 of 75
Most frequent serious events
EventPhase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
ATRIAL FIBRILLATIONCardiac disorders1/60/90/60/90/360/200/31
PNEUMONIAInfections and infestations0/60/90/61/96/360/201/31
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations0/60/91/60/90/360/200/31
BACK PAINMusculoskeletal and connective tissue disorders0/60/91/60/90/360/200/31
MALIGNANT NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/91/60/94/360/202/31
RENAL FAILURERenal and urinary disorders0/60/91/60/90/360/200/31
ABDOMINAL PAIN UPPERGastrointestinal disorders0/61/90/60/90/360/200/31
PAINGeneral disorders0/61/90/61/90/360/200/31
PYREXIAGeneral disorders0/61/90/61/90/360/200/31
RESPIRATORY TRACT INFECTION VIRALInfections and infestations0/60/90/61/90/360/200/31
Most frequent other events
Showing 10 of 190
Most frequent other events
EventPhase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg
NAUSEAGastrointestinal disorders1/66/93/65/918/365/2010/31
DIARRHOEAGastrointestinal disorders2/64/92/65/913/367/2012/31
DIZZINESSNervous system disorders1/60/93/60/94/361/204/31
THROMBOCYTOPENIABlood and lymphatic system disorders0/64/91/60/94/361/201/31
VOMITINGGastrointestinal disorders1/64/92/62/94/362/205/31
FATIGUEGeneral disorders2/61/90/62/915/362/209/31
HYPOPHOSPHATAEMIAMetabolism and nutrition disorders0/61/91/60/96/368/203/31
INSOMNIAPsychiatric disorders0/61/90/60/95/368/206/31
WHITE BLOOD CELL COUNT DECREASEDInvestigations0/60/90/61/913/365/201/31
ANAEMIABlood and lymphatic system disorders1/63/91/63/95/362/207/31

Baseline characteristics

Intent-to-Treat (ITT) population: all participants who received at least one dose of study drug

Age, Continuous
Age, Continuous(years)Phase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mgTotal
Mean62.0 ± 7.3263.1 ± 9.0361.8 ± 12.0667.3 ± 8.3260.8 ± 10.5863.4 ± 8.1364.9 ± 8.3163.1 ± 9.25
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mgTotal
Female12552331352
Male571413171865
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1: Venetoclax 300 mgPhase 1: Venetoclax 600 mgPhase 1: Venetoclax 900 mgPhase 1: Venetoclax 1200 mgPhase 1 Safety Expansion: Venetoclax 1200 mgPhase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mgPhase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mgTotal
White6946341724100
Black001122511
Asian00000011
American Indian or Alaska Native00000000
Native Hawaiian or other Pacific Islander00000000
Multi Race00000000
Other00000000
Missing00120115
08

Study locations

29 sites
  • Mayo Clinic - Scottsdale /ID# 75808
    Scottsdale, Arizona 85259-5452, United States
  • University of Arkansas for Medical Sciences /ID# 170002
    Little Rock, Arkansas 72205, United States
  • Yale University /ID# 203704
    New Haven, Connecticut 06510, United States
  • Emory University, Winship Cancer Institute /ID# 74993
    Atlanta, Georgia 30322, United States
  • Ingalls Memorial Hosp /ID# 205346
    Harvey, Illinois 60426, United States
  • Tulane Cancer Center Clinic /ID# 204123
    New Orleans, Louisiana 70112, United States
  • Tufts Medical Center /ID# 203814
    Boston, Massachusetts 02111-1552, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 170007
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic - Rochester /ID# 74994
    Rochester, Minnesota 55905-0001, United States
  • Hattiesburg Clinic /ID# 201187
    Hattiesburg, Mississippi 39401, United States
  • Washington University-School of Medicine /ID# 76094
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center /ID# 169158
    Omaha, Nebraska 68198-6840, United States
  • The John Theurer Cancer /ID# 200248
    Hackensack, New Jersey 07601, United States
  • Duke Cancer Center /ID# 129356
    Durham, North Carolina 27710-3000, United States
  • University Hospitals - Seidman Cancer Center /ID# 204502
    Cleveland, Ohio 44106-1716, United States
  • Ohio State Cancer Center /ID# 200249
    Columbus, Ohio 43210, United States
  • Avera Cancer Institute /ID# 204178
    Sioux Falls, South Dakota 57105, United States
  • Baylor University Medical Ctr. /ID# 170056
    Dallas, Texas 75246, United States
  • Swedish Cancer Institute - Edmonds /ID# 170006
    Seattle, Washington 98104, United States
  • Univ of Wisconsin Hosp/Clinics /ID# 200246
    Madison, Wisconsin 53792-0001, United States
  • Medical College of Wisconsin /ID# 205229
    Milwaukee, Wisconsin 53226-3522, United States
  • UZ Brussel /ID# 170711
    Jette, Bruxelles-Capitale 1090, Belgium
  • ZNA Stuivenberg /ID# 170067
    Antwerp, 2060, Belgium
  • Duplicate_University Hospital Leuven /ID# 170715
    Leuven, 3000, Belgium
  • CHRU Lille - Hopital Claude Huriez /ID# 74995
    Lille, Hauts-de-France 59037, France
  • CHRU Tours - Hopital Bretonneau /ID# 126639
    Tours CEDEX 9, Indre-et-Loire 37044, France
  • CHU de Nantes, Hotel Dieu -HME /ID# 75033
    Nantes, Pays-de-la-Loire 44000, France
  • Duplicate_CHU Grenoble - Hopital Michallon /ID# 126658
    Grenoble, 38043, France
  • Ulleval, OUS /ID# 170707
    Oslo, 0450, Norway
09

References and documents

Publications

  • Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10. PubMed 29018077 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Nov 2021, 109 months.

Results were first posted in Apr 2023, 1 year 4 months after primary completion.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 109 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2012
First posted
Feb 20, 2013
StartActual
Oct 10, 2012
Primary completionActual
Nov 29, 2021
CompletionActual
Nov 29, 2021
Results first posted
Apr 10, 2023
Last update
Apr 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01794520
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 20, 2013
Start date
Oct 10, 2012
Primary completion
Nov 29, 2021
Completion
Nov 29, 2021
Results posted
Apr 10, 2023
Last update
Apr 10, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion